Assay News and Research

RSS

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

The U.S. Food and Drug Administration today approved a second test to screen blood, tissue and organ donors for a blood-borne parasite, Trypanosoma cruzi that causes Chagas disease, a serious and potentially fatal parasitic infection.

3 May 2010

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe Incorporated today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share of $0.48 on both a non-GAAP and GAAP basis.

30 Apr 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

RedPath Integrated Pathology, Inc., a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has entered into a binding agreement to be acquired by ExonHit Therapeutics, S.A., a leading French diagnostics and therapeutics biotech company for an upfront payment of $12.5M in cash and $10M in stock, and starting in 2012, subsequent additional payment up to $9.5M dependent on the achievement of sales targets.

27 Apr 2010

ATCC introduces CRMs for method validation and method-performance verification

ATCC announces the launch of Certified Reference Materials, issued under ISO Guide 34 and ISO 17025:2005 accredited and ISO 9001:2008 certified laboratories. As a certified reference material producer, the combined accreditations demonstrate the highest level of quality assurance, accuracy and traceability for ATCC customers.

26 Apr 2010

SQI Diagnostics signs development agreement with Silliker

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it has entered into a development agreement with Silliker, Inc., a leading internationally accredited company dedicated to improving nutrition, food safety and quality, for the commercialization of a botulism toxin panel that will run on SQI's SQiDman analytical system.

26 Apr 2010

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

The authors of a recent peer-reviewed study published in the International Journal of Tuberculosis and Lung Disease confirmed the high specificity of the T-SPOT.TB assay.

26 Apr 2010

New reprogramming strategies needed for production of iPSCs: Study

Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. In a study that will appear in the journal Nature and is receiving early online release, investigators from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute (HSCI), describe finding that an important cluster of genes is inactivated in induced pluripotent stem cells (iPSCs) that do not have the full development potential of embryonic stem cells.

26 Apr 2010

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.

24 Apr 2010

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained.

23 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Elan's first-quarter total revenue up by 27% to $310.5M

Elan Corporation, plc, today reported its first quarter 2010 financial results.

21 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

AMRI extends and expands research collaboration with CHDI Foundation

AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington's disease (HD).

20 Apr 2010

Assay News and Research

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

Study results from US Military Malaria Vaccine Program announced

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

ATCC introduces CRMs for method validation and method-performance verification

SQI Diagnostics signs development agreement with Silliker

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

New reprogramming strategies needed for production of iPSCs: Study

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Elan's first-quarter total revenue up by 27% to $310.5M

ForteBio introduces new Octet QK(e) instrumentation system

AMRI extends and expands research collaboration with CHDI Foundation

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News